Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01696461 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor
A Phase 2 study, sponsored by Center for International Blood and Marrow Transplant Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 127
- Enrollment target
NCT01696461 is a Phase 2 study that has completed, run by Center for International Blood and Marrow Transplant Research. The registered enrollment target is 127 participants.
The verdict
NCT01696461, a Phase 2 study, has completed, sponsored by Center for International Blood and Marrow Transplant Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 127 participants
- Enrollment target
Study Summary
This is a Phase II, open-label, two strata, multicenter, prospective study of plerixafor-mobilized HLA-identical sibling allografts in recipients with hematological malignancies. This study will establish the safety and efficacy of subcutaneous plerixafor for this purpose.
Interventions
- DRUG Plerixafor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 127 participants |
| Start Date | 2013-05 |
| Est. Completion | 2016-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01696461
The ClinicalTrials.gov registry entry for NCT01696461 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 127 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Center for International Blood and Marrow Transplant Research, which has 29 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Plerixafor is the first listed.
NCT01696461 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01696461 about?
NCT01696461 is a clinical study titled "A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor". This is a Phase II, open-label, two strata, multicenter, prospective study of plerixafor-mobilized HLA-identical sibling allografts in recipients with hematological malignancies. This study will establish the safety and efficacy of subcutaneous plerixafor for this purpose.
What is the current status of trial NCT01696461?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 127 participants. The study started on 2013-05. Estimated completion is 2016-08.
What interventions are being tested in trial NCT01696461?
The interventions under investigation include: Plerixafor (DRUG).
Who is sponsoring clinical trial NCT01696461?
This trial is sponsored by Center for International Blood and Marrow Transplant Research, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.